Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance
Provided By GlobeNewswire
Last update: May 7, 2025
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 --
-- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 --
Read more at globenewswire.com
